Scarica l'app Stockscreener
10.11
0.80%
0.08
Precedente Chiudi:
$10.03
Aprire:
$10.05
Volume 24 ore:
739.79K
Relative Volume:
0.40
Capitalizzazione di mercato:
$539.13M
Reddito:
$1.02B
Utile/perdita netta:
$-757.20M
Rapporto P/E:
-0.8369
EPS:
-12.08
Flusso di cassa netto:
$-257.90M
1 W Prestazione:
+13.85%
1M Prestazione:
+13.21%
6M Prestazione:
+112.39%
1 anno Prestazione:
+388.41%
Intervallo 1D:
$9.84
$10.33
Intervallo di 1 settimana:
$8.83
$10.33
Portata 52W:
$1.42
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Confronta EBS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
10.11 | 539.13M | 1.02B | -757.20M | -257.90M | -12.08 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Emergent's Vaccine Production Failure: Contamination Scandal, Investor Backlash, and $40M Settlement - Benzinga
Emergent BioSolutions Inc. (NYSE:EBS) Q3 2024 Earnings Call Transcript - MSN
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
Insider Sale: Director Donald Degolyer Sells 25,000 Shares of Em - GuruFocus.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock - Investing.com
Emergent BioSolutions director Donald DeGolyer sells $272,750 in stock By Investing.com - Investing.com UK
Oak Hill Advisors LP's Strategic Acquisition of Emergent BioSolu - GuruFocus.com
Insider Sale: Director Marvin White Sells 14,287 Shares of Emergent BioSolutions Inc (EBS) - GuruFocus.com
Smallpox Treatment Market Is Anticipated To Grow In A Promising - openPR
Emergent BioSolutions Inc (EBS) Shares Down 8.02% on Nov 12 - GuruFocus.com
IDWeek 2024: strategic approaches and challenges in mpox vaccination - Pharmaceutical Technology
Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Emergent BioSolutions (NYSE:EBS) Shares Up 7.9% After Analyst Upgrade - MarketBeat
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights - GuruFocus.com
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic (NYSE:EBS) - Seeking Alpha
Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong - MSN
Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise - Benzinga
Emergent BioSolutions Inc (EBS) Quarterly 10-Q Report - Quartzy
Emergent BioSolutions entering ‘turnaround’ phase, new CEO says - The Business Journals
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 - Yahoo Finance
Crude Oil Rises 1%; US Jobless Claims Increase To 221,000 - Benzinga
Emergent BioSolutions (NYSE:EBS) Shares Gap Up on Analyst Upgrade - MarketBeat
Emergent Biosolutions Shares Surge 28% After Swinging to 3Q Profit - MarketWatch
Emergent BioSolutions stock target increased, keeps buy on strong Q3 By Investing.com - Investing.com UK
The Post-Trump Victory TradeEmergent BioSolutions (NYSE:EBS), Bit Digital (NASDAQ:BTBT) - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Emergent Biosolutions: Q3 Earnings Snapshot - Houston Chronicle
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript - AOL
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates - Yahoo Finance
Emergent Biosolutions stock jumps 14% post-market on guidance raise (NYSE:EBS) - Seeking Alpha
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa - The Manila Times
The Escalator: Emergent BioSolutions, CureVac, Kyowa Kirin and more - MM+M Online
Emergent BioSolutions Reports Third Quarter 2024 Financial Results - The Manila Times
Emergent BioSolutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Emergent Bio slips after financing deal - MSN
Emergent BioSolutions appoints new chief medical officer By Investing.com - Investing.com Canada
Biotech Co. Emergent Gives Interim GC Permanent Role - Law360
Emergent BioSolutions appoints new chief medical officer - Investing.com
Emergent BioSolutions (EBS) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Emergent Bio's smallpox vaccine gets US approval for mpox - AOL
Assenagon Asset Management S.A. Increases Stock Position in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - Simply Wall St
Zacks.com featured highlights include American Airlines, Air Canada, EmergentBioSolutions, Berry and Cracker Barrel Old Country Store - Yahoo Finance
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades - Yahoo Finance
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - GlobeNewswire Inc.
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 - The Manila Times
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference - The Bakersfield Californian
Emergent BioSolutions (NYSE:EBS) Shares Up 3.2%Here's What Happened - MarketBeat
Biopharma Layoffs Roundup - Contract Pharma
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):